Ureaplasma Urealyticum

If you are trying to conceive, currently pregnant, or chasing down the cause of unexplained urogenital symptoms, this is one of the tests that the usual chlamydia and gonorrhea panel will not run for you. A vaginal swab for UU (Ureaplasma urealyticum) looks for a tiny bacterium that lives in the genital tract of a large share of sexually active women, often without any symptoms at all.

The reason to care is not that every positive result means trouble. It is that in specific situations, particularly pregnancy, infertility work-ups, and persistent urogenital symptoms, knowing whether this organism is present changes what comes next. Researchers have linked genital Ureaplasma species to preterm birth, premature rupture of membranes, chorioamnionitis, and serious newborn complications, especially when bacterial load is high or the infection moves beyond the lower genital tract.

What This Test Actually Detects

UU is a very small bacterium without a cell wall, which is part of why it dodges some standard antibiotics like penicillin. It grows by breaking down urea. A vaginal swab test detects whether the organism is present in your lower genital tract and, depending on the method used, can estimate how much of it is there. Modern testing typically uses molecular methods (PCR) that can separate U. urealyticum from its close cousin U. parvum, which matters because older culture kits often lumped the two together and overcalled UU.

Across large outpatient studies in China, UU was the most frequently detected genital tract pathogen, found in a substantial share of gynecology patients tested. In Beijing, a large fraction of married women had it on cervical or vaginal swabs. In one Papua New Guinea study, carriage was very high. The point: detection alone is common. What matters is the clinical context around it.

Pregnancy and Preterm Birth Risk

This is the strongest area of evidence and the most important reason to know your status if you are pregnant or planning to be. Genital Ureaplasma species have been linked to preterm birth, premature rupture of membranes, chorioamnionitis (infection of the membranes surrounding the baby), low birth weight, and perinatal death.

An important nuance: in larger and more recent studies, the strongest independent association with spontaneous preterm birth is actually with U. parvum, not U. urealyticum. A prospective multicenter study of 4,330 pregnant women found that first-trimester vaginal colonization with U. parvum was an independent risk factor for spontaneous preterm birth (adjusted OR 1.6, 95% CI 1.2–2.1), while U. urealyticum colonization was not. A 2026 meta-analysis of 156 studies similarly found cervicovaginal U. parvum significantly associated with preterm birth (OR 1.63, 95% CI 1.36–1.96). This is part of why species-specific PCR matters: culture-based methods that lump the two organisms together can blur which species is driving risk.

That said, U. urealyticum is not without signal in pregnancy. A prospective study tracking second-trimester amniotic fluid found that a substantially higher proportion of women whose fluid tested positive for UU went on to deliver preterm, compared with women who tested negative. In another cohort, women with high cervical UU load had a higher independent risk of preterm birth before 32 weeks of pregnancy.

The pattern that emerges across studies: simple presence of either Ureaplasma species in the lower genital tract is common and often harmless. The risk climbs sharply when the organism rises into the upper genital tract, when the bacterial load is high, or when it shows up alongside bacterial vaginosis.

Newborn Health

UU in the maternal genital tract can be passed to the newborn during delivery. Studies have reported vertical transmission rates of roughly 18–68% from colonized mothers to neonates, varying by gestational age, delivery mode, and population. Premature infants exposed to UU face higher rates of bronchopulmonary dysplasia (a serious lung condition of preterm infants), brain injury, sepsis, severe pneumonia, and increased mortality. A separate analysis showed that detecting UU in both placenta and neonatal urine identified preterm infants at the highest risk for complications, suggesting that the spread and burden of the organism, not just its presence, drive harm.

Fertility, Sperm Quality, and Urogenital Inflammation

UU has been linked to lower sperm concentrations and reduced forward-moving sperm in studies of men evaluated for infertility, where UU was the most frequently isolated single pathogen in one large cohort (about 37.6% of positive cultures). In a separate analysis of men with urogenital UU or Mycoplasma hominis infection, semen showed higher inflammatory markers, reduced sperm quality, and increased DNA fragmentation compared with men without these infections. For couples in a fertility work-up, finding UU in one or both partners can change the treatment plan.

In women, UU is frequently found in mixed infections alongside chlamydia, gonorrhea, bacterial vaginosis organisms, and HPV (human papillomavirus). The presence of multiple pathogens at once can complicate symptoms and treatment, and routine syndromic care without testing can miss the actual mix of organisms involved.

Why a Positive Result Does Not Always Mean Disease

This is the single most important nuance about UU. In one study, U. parvum and U. urealyticum were found at the same frequency in women with and without symptoms of urogenital tract infection. In another analysis of more than 1,200 nonpregnant women, UU detection was not associated with genital symptoms or signs, leading the authors to advise against routine testing in nonpregnant women without a clinical reason. A study comparing cervicitis cases and asymptomatic controls found no significant difference in UU load between the two.

So a positive vaginal swab can mean colonization (the organism lives there without causing problems) rather than infection. Interpretation depends on whether you are pregnant, whether you have symptoms, whether the bacterial load is high, whether it appears alongside bacterial vaginosis, and whether there is evidence of upper genital tract involvement.

When Results Can Be Misleading

A handful of factors can shift what your test report means without changing your actual biology:

• Test method matters: older culture kits often cannot distinguish U. urealyticum from U. parvum and may misclassify one as the other. In one comparison, culture flagged UU as positive in a much larger proportion of pregnant women than species-specific PCR confirmed. If your lab uses culture, treat the species call cautiously.
• Recent antibiotic use: any antibiotic with activity against this class of bacteria can suppress the organism temporarily, causing a false-negative result. If you have taken antibiotics in the past few weeks, mention that when interpreting your result.
• Collection technique: vaginal swabs require an adequate sample from the right site. Inadequate sampling can produce a false negative. A urinary swab is more accurate than a urine specimen for detecting UU in women with lower urinary tract symptoms.
• Coinfections: UU is frequently found alongside chlamydia, gonorrhea, bacterial vaginosis, and HPV. A positive result for UU alone does not rule out other organisms, and a positive result for one does not necessarily explain your symptoms.

Why One Reading Is Not Enough

UU is a dynamic biological state, not a fixed genetic trait. Carriage can come and go with sexual exposure, antibiotic use, and natural changes in the vaginal microbiome. A single negative result is a snapshot. A single positive result needs context: are there symptoms, is there pregnancy, what is the bacterial load, are there coinfections?

If you test positive and are pregnant or planning to conceive, a reasonable approach is to confirm with a species-specific PCR test if your initial result came from culture, then retest after any treatment to confirm clearance. If you are not pregnant and have no symptoms, repeat testing without a clinical reason is generally not recommended. For symptomatic infections, retest 3 to 4 weeks after completing antibiotics to confirm the organism is gone, since persistent detection after treatment is common even when symptoms resolve.

Decision Pathway for an Unexpected Result

A positive UU swab is the start of a conversation, not the end of one. The combination of findings is what determines next steps.

• Positive UU, pregnant, with symptoms or risk factors for preterm birth: this is the highest-priority scenario. Discuss with an obstetrician familiar with genital mycoplasma infections. Companion tests typically include bacterial vaginosis evaluation, chlamydia and gonorrhea NAAT, and assessment for upper genital tract involvement when clinically warranted.
• Positive UU, infertility work-up: pair with semen analysis if male partner is being evaluated, plus testing for chlamydia, gonorrhea, Mycoplasma genitalium, and bacterial vaginosis. A reproductive endocrinologist or urologist can coordinate next steps.
• Positive UU, nonpregnant, with symptoms: evaluate for other STIs (sexually transmitted infections), bacterial vaginosis, and yeast. Treatment is typically considered only after excluding more common causes of symptoms.
• Positive UU, nonpregnant, no symptoms: this is the scenario where IDSA/ASM 2024 guidance and recent meta-analyses specifically discourage routine screening or treatment, because evidence that treating asymptomatic colonization helps is lacking. Watch and reassess if symptoms develop or pregnancy is being planned.

If your test method was culture-based and labeled the result as U. urealyticum, consider confirming with a species-specific PCR test before acting, because misclassification is common.

Antibiotic Sensitivity Patterns

When treatment is warranted, choice of antibiotic matters because UU lacks a cell wall (making penicillin and similar drugs useless against it) and because resistance patterns vary by region. In North American surveillance, Ureaplasma isolates show low resistance to doxycycline (tetracycline resistance around 6.5%) and to erythromycin (around 2.4%), with doxycycline remaining the most active tetracycline. A meta-analysis found azithromycin highly effective for UU, with cure rates comparable to doxycycline. In pregnant women, resistance patterns vary by region; tetracyclines and many fluoroquinolones are typically avoided in pregnancy.